Drug Trial Radar · NCT07174063
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
Nov 26, 2025
Primary completion
Jan 29, 2027
Study completion Jan 29, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase I study aims to evaluate the safety, tolerability and PK of JSB462 in Japanese patients with metastatic prostate cancer.
Conditions
- Metastatic Prostate Cancer (mCRPC)
Interventions
JSB462Drug
300 mg or 100 mg once a day (QD) with food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatmentTime frame: Up to 28 days
- Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Through study completion, an average of approximately 18 months
- Number of Participants with dose adjustmentsTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 18 months
- Dose IntensityTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 18 months
- Plasma concentrations of JSB462 and its metabolite ARV-767Time frame: Cycle 1: Days 1 & 21 (0 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours), Days 2 & 22 (0 hour). Cycles 2-6: Day 1 (0 hour). End of Treatment Visit (EOT): within 7 days from the last dose of JSB462. 1 cycle = 28 days.
- AUC of JSB462Time frame: Cycle 1: Days 1 & 21 (0 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours), Days 2 & 22 (0 hour). Cycles 2-6: Day 1 (0 hour). End of Treatment Visit (EOT): within 7 days from the last dose of JSB462. 1 cycle = 28 days.
- Cmax of JSB462Time frame: Cycle 1: Days 1 & 21 (0 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours), Days 2 & 22 (0 hour). Cycles 2-6: Day 1 (0 hour). End of Treatment Visit (EOT): within 7 days from the last dose of JSB462. 1 cycle = 28 days.
- Tmax of JSB462Time frame: Cycle 1: Days 1 & 21 (0 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours), Days 2 & 22 (0 hour). Cycles 2-6: Day 1 (0 hour). End of Treatment Visit (EOT): within 7 days from the last dose of JSB462. 1 cycle = 28 days.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Kobe, Hyōgo, Japan
Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site
Koto Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.